Hindustan Bio Sciences Ltd has unveiled a capital restructuring scheme to address accumulated losses on its balance sheet. The company plans to cancel over 5.6 million shares and consolidate its equity in a 1:5 ratio. This accounting-focused exercise aims to reflect a truer financial position without impacting existing shareholding percentages or providing cash payouts to investors. The plan now moves toward shareholder and NCLT approval.
Hindustan Bio Sciences Announces Capital Reduction and Consolidation
Cancellation of 56,37,940 equity shares and consolidation of shares in a 1:5 ratio.
Reader Takeaway: This is a balance-sheet cleanup to remove accumulated losses; operational strategy and shareholding percentages remain unchanged.
What just happened
Hindustan Bio Sciences Ltd has approved a comprehensive Scheme of Reduction of Capital and re-organisation. The company will cancel 56,37,940 equity shares of Rs 2 each to offset accumulated losses amounting to Rs 1.13 crore. Following the reduction, the company will consolidate its equity, converting 5 shares of Rs 2 face value into 1 share of Rs 10 face value.
Why this matters
The restructuring is an accounting measure intended to provide a clear and fair view of the company's financial position by wiping out historical losses. For investors, this is a non-cash event. The company has confirmed that relative shareholding percentages for continuing shareholders will remain unchanged after the process concludes. No special benefit or additional gain accrues to the promoter group through this reduction.
What changes now
Post-reduction and consolidation, the company’s capital base will be realigned into 9,22,572 equity shares of Rs 10 each. Shareholders will receive 9 shares of Rs 10 face value for every 100 shares of Rs 2 held. Any fractional entitlements resulting from the consolidation will be rounded off, with the promoter, Mr. Venkata Rama Mohan Raju Jampana, committing to forgo rounding-related share increases to maintain the target capital structure.
What to track next
The plan is subject to mandatory approvals from the company's shareholders and the Hyderabad Bench of the National Company Law Tribunal (NCLT). Investors should monitor upcoming AGM filings for specific timelines and formal voting procedures regarding the restructuring scheme.